Conventional type 1 dendritic cells (cDC1) in cancer immunity
Peng Liu, Liwei Zhao, Guido Kroemer, Oliver Kepp
Abstract
Cancer immunotherapy, alone or in combination with conventional therapies, has revolutionized the landscape of antineoplastic treatments, with dendritic cells (DC) emerging as key orchestrators of anti-tumor immune responses. Among the distinct DC subsets, conventional type 1 dendritic cells (cDC1) have gained prominence due to their unique ability to cross-present antigens and activate cytotoxic T lymphocytes. This review summarizes the distinctive characteristics of cDC1, their pivotal role in anticancer immunity, and the potential applications of cDC1-based strategies in immunotherapy.
Topics & Concepts
BiologyImmunotherapyCytotoxic T cellImmune systemDendritic cellCancer immunotherapyCancerAntigenImmunologyImmunityCancer researchGeneticsIn vitroImmunotherapy and Immune ResponsesT-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers